Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

Aims/hypothesis The best treatment strategy for a patient with type 2 diabetes who shows pronounced weight gain after the introduction of insulin treatment is unclear. We determined whether addition of a glucagon-like peptide-1 (GLP-1) analogue could reverse pronounced insulin-associated weight gain...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2014-09, Vol.57 (9), p.1812-1819
Hauptverfasser:	de Wit, Helena M., Vervoort, Gerald M. M., Jansen, Henry J., de Grauw, Wim J. C., de Galan, Bastiaan E., Tack, Cees J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences Blood Glucose - drug effects Clinical trials Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Drug dosages Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glucagon Glucagon-Like Peptide 1 - analogs & derivatives Glucagon-Like Peptide 1 - therapeutic use Glucose Human Physiology Humans Hypoglycemia Hypoglycemic Agents - therapeutic use Hypotheses Insulin Insulin - administration & dosage Insulin - therapeutic use Internal Medicine Liraglutide Male Medical sciences Medicine Medicine & Public Health Metabolic Diseases Middle Aged Peptides Teaching hospitals Weight Gain - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!